John Lahart
Question:264. Deputy John Lahart asked the Minister for Health for a timeline on the consultation process committed to in respect of drug cost reimbursement including the cost of drugs for rare diseases. [25387/23]
View answerThursday, 25 May 2023
Questions (264)
Written answers
In February, I published the Mazars Review which examined the governance arrangements around the HSE’s Drug Pricing and Reimbursement Process. I fully support the recommendations contained in the Mazars report around improving the process, increasing transparency, providing easier access, and supporting value for money.
An implementation group has been established between my Department and the HSE to consider and progress the various recommendations contained in the Report. The Group has met and will shortly engage with stakeholders including patient groups and industry, in seeking to bring about further improvements to the reimbursement process.
The membership of the Group includes representatives of the Drugs Group, the HSE, the NCPE, and the Department of Health.